# Chimeric Switch Receptors to Potentiate CAR T Cell Therapy for Solid Tumor Cancers

> **NIH NIH R43** · JAVELIN ONCOLOGY, INC. · 2022 · $328,946

## Abstract

Project Abstract/Summary
Cancer is expected to claim 8.8 million lives worldwide this year. In the US, it is the leading cause of death with
a prevalence that continues to grow each year. Conventional treatment options tend to be limited in efficacy
and are often accompanied by deleterious side effects. Newer antibody-based and cell-based therapies have
shown particular promise for a subset of solid tumor and hematological cancers, respectively. Importantly,
while these new therapies have shown promise, they are often only effective in a small cross-section of
patients or are accompanied by severe side effects. Solid tumor cancer patients tend to have the poorest
prognoses and outcomes. This is likely due strong suppression of patients’ immune systems driven by cancer
cell signaling. This proposal aims to overcome key mechanisms of immune suppression in the tumor
microenvironment to unlock the full potential of new classes of cancer therapeutics. Importantly, the technology
leverages alternative signaling pathways which show promise for enhancing immune system function.
With this Phase I SBIR, Javelin Oncology intends to provide preclinical proof-of-concept that a novel
therapeutic can enhance the function of the current generation of cellular therapies to unlock their potential for
treating solid cancers. These experiments will drive the selection of a lead therapeutic and justify the IND-
enabling preclinical work required to prepare these novel therapeutics for delivery to patients.

## Key facts

- **NIH application ID:** 10483928
- **Project number:** 1R43CA271934-01
- **Recipient organization:** JAVELIN ONCOLOGY, INC.
- **Principal Investigator:** Anthony Cooper
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $328,946
- **Award type:** 1
- **Project period:** 2022-07-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10483928

## Citation

> US National Institutes of Health, RePORTER application 10483928, Chimeric Switch Receptors to Potentiate CAR T Cell Therapy for Solid Tumor Cancers (1R43CA271934-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10483928. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*